Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C

Liver International

Volumn 26, Issue 2, 2006, Pages 166-172

  Wu, Yu Jian ^a   Chen, Li Shu ^a   Qiang, Wang Gui ^b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Fatty liver; Genotype; Hepatitis C; Insulin; Sustained virologic response

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ANTHROPOMETRY; ARTICLE; B SCAN; BODY MASS; CALCULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; FATTY LIVER; FEMALE; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIVIRAL AGENTS; CHINA; DRUG THERAPY, COMBINATION; FATTY LIVER; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN RESISTANCE; INTERFERON ALFA-2A; MALE; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 33645968108     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01219.x     Document Type: Article

References (33)

1. Sarbah S A, Younossi Z M. Hepatitis C: An update on the silent epidemic. J Clin Gastroenterol 2000; 30: 125-43.
2. Liang T J, Rehermann B, Seeff L B, Hoofnagle J H. Pathogenesis, nature history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132: 296-305.
3. National Institutes of Health consensus development conference statement. Management of hepatitis C. Hepatology 2002; 36: S3-20.
4. Younossi Z M, McCullough A J, Ong J P, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 2004; 38: 705-9.
5. Day C P. Non-alcoholic stetohepatitis (NASH): Where are we now and where are we going? Gut 2002; 50 (5): 585-8.
6. Lafaine M, Mauricio L-M. Nonalcoholic fatty liver disease. Annal Hepatol 2004; 3 (3): 93-9.
7. Serfaty L, Andreani T, Giral P, et al. Hepatitis C virus induced hypobetalipoproteinemia: A possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34 (3): 428-34.
8. Narita R, Abe S, Kihara Y, Akiyama T, Tabaru A, Otsuki M. Insulin resistance and insulin secretion in chronic hepatitis C virus infection. J Hepatol 2004; 41: 132-8.
9. Konrad T, Zeuzem S, Toffolo G, et al. Severity of HCV-induced liver damage alters glucose homeostasis in noncirrhotic patients with chronic HCV infection. Digestion 2000; 62: 52-9.
10. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes 2001; 50 (8): 1844-50.
11. Liu C J, Jeng Y M, Chen P J, et al. Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C. Antiviral Ther 2005; 10 (3): 405-15.
12. Petit J M, Bour J B, Galland-Jos C, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001; 35 (2): 279-83.
13. Adinolfi L E, Gambardella M, Andreana A, Tripodi M F, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33 (6): 1358-64.
14. Hui J M, Sud A, Farrell G C, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gasteoenterology 2003; 125: 1695-704.
15. Poynard T, Ratziu V, Mchutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85.
16. Sanyal A J, Chand N, Comar K, Mirshahi F. Hyperinsulinemia blocks the inhibition of hepatitis C virus (HCV) replication by interferon: A potential mechanism for failure of interferon therapy in subjects with HCV and nonalcoholic liver disease. Hepatology 2004; 40 (4 Suppl. 1): 179A.
17. Hoofnagle J H, Ghany M G, Kleiner D E, et al. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology 2003; 38: 66-74.
18. Stuyver L, Wyseur A, van Arnhem W, et al. Hepatitis C virus genotyping by means of 5-UR/core line probe assays and molecular analysis of untypeable samples. Virus Res 1995; 38: 137-57.
19. Kobayashi M, Chayama K, Arase Y, et al. Enzyme-linked immunosorbent assay to detect hepatitis C virus serological groups 1 to 6. J Gastroenterol 1999; 34: 505-9.
20. Yajima Y, Ohta K, Narui T, Abe R, Suzuki H, Ohtsuki M. Ultrasonographical diagnosis of fatty liver: Significance of the liver-kidney contrast. Tohoku J Exp Med 1983; 139: 43-50.
21. Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
22. Davidson F, Simmonds P, Ferguson J C, et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′ non-coding region. J Gen Virol 1995; 76: 1197-204.
23. Xie Y, Xu D Z, Lu Z M, et al. The influnce of HCV genotype on the IFN treatment of patients with chronic hepatitis C. Zhonghua Gangzangbing Zazhi 2004; 12: 72-5.
24. Bidceglie Di A M, Hoofnagle J H. Optimal therapy of hepatitis. Hepatology 2002; 36: S121-7.
25. Michael W, Fried M D. Vrial factors affecting to the outcome of therapy for chronic hepatitis C. Rev Gastroenterol Disord 2004; 4: S8-13.
26. Castéra L, Hézode C, Roudot-Thoraval F, et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003; 52: 288-92.
27. Colin A B, Linda S A, Popkin B M. Ethnic differences in the association between body mass index and hypertension. Am J Epidemiol 2002; 155: 346-53.
28. Saadeh S, Younossi Z M, Remer E M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.
29. Rubbia-Brandt L, Leandr G o, Spahr L, et al. Liver steatosis in chronic hepatitis C: A morphological sign suggesting infection with HCV genotype 3. Histopathology 2001; 39: 119-24.
30. Bressler B L, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-44.
31. Chitturi S, Abeygunasekera S, Farrell G C, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35 (2): 373-9.
32. Marchesini G, Brizi M, Morselli-Labate A M, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107 (5): 450-5.
33. Day C P, James O F. Steatohepatitis: A tale of two "hits"? Gastroenterology 1998; 114 (4): 42-5.